Bionor’s 3rd vaccine candidate, Vacc-CRX, Proof of Mechanism established

Oslo, January 23, 2019. Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, Vacc-CRX. This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors and facilitate virus neutralization. Lead optimization and drug characterization with Proof of Principle will be established within the next 6 – …

Read more

New strategy for combining Vacc-4x and Vacc-C5 with a defined path that can lead to a regulatory approval and commercialization

Bionor’s strategy is to develop the combination of its two proprietary therapeutic HIV vaccines Vacc-4x and Vacc-C5 and seek advice on and adapt its regulatory path so that a marketing approval for a functional cure for HIV can be achieved. As part of this strategy, Bionor will extend and complete the Vacc-C5 dose escalation studies …

Read more